iTeos Therapeutics, Inc.

ITOSNASDAQHealthcare

$10.15

+$0.02(+0.20%)

Market Cap$448684810

P/E Ratio—

52W High$17.63

52W Low$4.8

Avg Volume1.3M

Open$10.15

Beta1.49

Overview

iTeos Therapeutics, Inc. (ITOS) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

ITOS · net income · updated Jun 9, 2026

Core profitability metrics

ITOS · net income · margin · TTM · CAGR

Net income was −$134.4M for FY2024 (fiscal year ending 2024-12-31), down 19.3% year-over-year. Net profit margin was -384.0%. Based on available data, iTeos Therapeutics, Inc. has been profitable since at least 2021.

FY2024 Net Income−$134.4M▼ -19.3% YoY

Trailing 12M (TTM)−$202.4Mtrailing 4 quarters sum

Net Profit Margin-384.0%−$134.4M ÷ $35.0M

YoY Change-19.3%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %★ First Profit: 2021

▸ FMP /income-statement · Annual · ITOS net income history · ITOS profit margin

Annual net income data

ITOS · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2024Loss−$134.4M▼ 19.3%-384.0%$35.0M

FY2023Loss−$112.6M▼ 216.5%-894.3%$12.6M

FY2022$96.7M▼ 54.9%36.1%$267.6M

FY2021★ First Profit$214.5M▲ +664.0%62.2%$344.8M

FY2020Loss−$38.0M▼ 69.4%—$0

Net income vs peers (Healthcare)

ITOS vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

iTeos Therapeutics, Inc.YOU

ITOS

−$134.4M-19.3%-384.0%

Loss

Eli Lilly and Company

LLY

$20.64B+94.9%31.7%

77%

UnitedHealth Group Incorporated

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

iTeos Therapeutics, Inc. (ITOS) reported net income of −$134.4M for FY2024 (fiscal year ending 2024-12-31), down 19.3% year-over-year. The net profit margin was -384.0% — meaning the company kept $-3.84 of every dollar of revenue as profit.

Based on available data, iTeos Therapeutics, Inc. has been profitable since at least 2021. Net income reached a peak of $214.5M in FY2021. Data available for 7 fiscal years.

iTeos Therapeutics, Inc.'s net profit margin was -384.0% for FY2024, based on the latest annual results.

Investors sometimes search for "iTeos Therapeutics, Inc. net worth" — the company's market capitalization is a separate figure from ITOS net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

ITOS net income · 4 questions

iTeos Therapeutics, Inc. is not currently profitable on an annual basis. The company reported a net loss of $134.4M for FY2024.

is ITOS profitabledoes ITOS make a profitITOS profitabilityITOS profitable company

▸ Source: FMP /income-statement · GAAP · iTeos Therapeutics, Inc. · iTeos Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026